New method of eradication therapy of Helicobacter pylori
Abstract
Introduction. The huge role of Helicobacter pylori in the development of a number of diseases, the importance of eradication of H.p. in the treatment of these diseases, and the prevention of stomach cancer on the background of reducing the effectiveness of the modes of the 1st line anti-H.p. therapy requires a search for new more effective modes. The aim of the study was to determine the effectiveness of the modified antihelicobacter therapy in combination with complex synbiotic preparation of Natuma Bactoflor 12+. Materials and methods. It was conducted a double-masked controlled study of a tailor-made protocol. In the 1st group (n = 31) patients received a 14-day modified sequential therapy (MSty on the background of a synbiotic preparation of Natuma Bactoflor 12+. In the 2nd group (n = 31) patients received only MST. The comparison group had not significant differences in all criteria, which could influence the final results of the study. Results. Eradication of H.p. in the 1st group of 93.5 % (ITT and 97 % (PP), respectively, in the 2nd group of 77.4 and 85.7 %. In total, the development of adverse events in the 1st group, with 19.4 % of all the surveyed and 20 % of patients treated according to protocol, and in the 2nd group respectively 38.7 and 42.9 % (p < 0.05). The activity of the inflammatory process in the mucosa of antrum and body of stomach had no differences before treatment and was significantly less after treatment in the study group when the adjuvant use Natuma Bactoflor 12+ than in the control group (p < 0.001). Conclusions. The use of Natuma Bactoflor 12+ on the background of modified sequential therapy, increases the percentage of eradication of H. pylori, reduces the severity of inflammation in gastric mucosa, reduces the frequency of adverse events among included and completed the study and increases compliance.
References
1. Libanio D, Azevedo LF. Analysis of the Cochrane Review: Helicobacter pylori Eradication for the Prevention of Gastric Neoplasia. Cochrane Database Syst. Rev.- 2015; 7: CD 005583.
2. Yi-Chia Lee et al. Association Between Helicobacter pylori Eradication and Gastric Cancer Incidence: A Systematic Review and Meta-analysis // Gastroenterology.- 2016; 1-11. DOI: 10.1053/j.gastro.2016.01.028.
3. Шапошников А. В. Колоректальный рак. Канцерогенез и онкопревенция: пособие для врачей. - Москва, 2015.- с. 160.
4. Sugano K, et al. Kyoto global consensus report on Helicobacter pylori gastritis // Gut.- 2015; 64: 1-15. DOI: 10.1136/ gutjnl-2015-309252.
5. Malfertheiner P, et al. Current concepts in the management of Helicobacter pylori infection: the Maastricht III Consensus Report // Gut.- 2007; 56 (6): 772-781. DOI: 10.1136/gut.2006.101634.
6. Chey W. D., Wong B. C.Y. American College of Gastroenterology Guideline on the Management of Helicobacter pylori Infection // Am. J. Gastroenterol.- 2007; 102 (8): 18081825. DOI: 10.1111/j.1572-0241.2007.01393.x.
7. Graham DY. Helicobacter pylori Update: Gastric Cancer, Reliable Therapy, and Possible Benefits // Gastroenterology.- 2015; 148: 719-731. DOI: http://dx.doi. org/10.1053/j.gastro.2015.01.040.
8. Yuan Y, et al. Optimum duration of regimens for Helicobacter pylori eradication (Review) // The Cochrane Library.-2013, Issue 12. DOI: 10.1002/14651858.CD008337.pub2.
9. Старостин Б. Д. Под редакцией проф. Ткаченко Е. И. Повышение эффективности эрадикации Helicobacter pylori при Н.р.-ассоциированных заболеваниях. Практические рекомендации и схемы терапии.- СПб.: Инфо Ол, 2015.-52 с.: ил.
10. Chang Liu, Zhuo-Yang Zhang, Ke Dong, Xiao-Kui Guo. Adhesion and immunomodulatory effects of Bidobacterium lactis HN 019 on intestinal epithelial cells INT-407 // WJG.- 2010; 16 (18): 2283-2290. DOI:10.3748/wjg. v16.i18.2283.
11. Achmed M, et al. Impact of consumption of different levels of Bifidobacterium lactis HN019 on the intestinalmicroflora of elderly human subjects // J. Nutr. Health Aging.- 2007; 11 (1): 26-31.
12. Technical Memorandum. TM 58-2e. Danisco. Bifidobacterium lactis HN 019 - a probiotic witH proven efficacy.
13. Bernini LJ, Simao AN, Alfieri DF, et al. Beneficial effects of Bifidobacterium lactis on lipid profile and cytokines in patients with metabolic syndrome: A randomized trial. Effects of probiotics on metabolic syndrome // Nutrition.- 2016; 32 (6): 716-9. DOI: 10.1016/j. nut.2015.11.001.
14. Sachdeva A, Rawat S, Nagpal J. Effcacy of fermented milk and whey proteins in Helicobacter pylori eradication: A review // WJG.- 2014; 20 (3): 724-737. DOI: 10.3748/wjg.v20.i3.724.
15. Ammons M. C. and Copie V. Lactoferrin: A bioinspired, anti-biofilm therapeutic //Biofouling.- 2013; 29 (4): 443-455. DOI: 10.1080/08927014.2013.773317.
16. Fulgione Andrea, et al. Lactoferrin Adsorbed onto Biomimetic Hydroxyapatite Nanocrystals Controlling - In Vivo - the Helicobacter pylori Infection // PLOS one.- 2016; Jule 6: 1-16. DOI:10.1371/journal.pone.0158646.
17. Sachdeva A & Nagpal J. Meta-analysis: efficacy of bovine lactoferrin in Helicobacter pylori eradication // Aliment Pharmacol Ther.- 2008; 29: 720-730. DOI:10.1111/ j.1365-2036.2009.03934.x.
18. Lebros-Pantoflickova D, Corthesy-Theulaz I, and Blum L. Helicobacter pylori and Probiotics // J. Nutr. - 2007; 137: 812S-818S.
19. Calvet X, Garcia N, Lopez T, et al. A meta-analysis of short versus long therapy with a proton pump inhibitor, clarithromycin and either metronidazole or amoxycillin for treating Helicobacter pylori infection // Aliment. Pharmacol. Ther.- 2000; 14: 603-9.
20. Ford A, Moayyedi P. How can the current strategies for Helicobacter pylori eradication therapy be improved? //Can. J. Gastroenterol.- 2003; 17 (Suppl. B): 36B-40B.
21. Peter Malfertheiner, Francis Megraud, Colm A O’Morain, John Atherton, Anthony T R Axon, Franco Bazzoli, Gian Franco Gensini, Javier P Gisbert, David Y Graham, Theodore Rokkas, Emad M El-Omar, Ernst J Kuipers, The European Helicobacter Study Group (EHSG). Management of Helicobacter pylori infection - the Maastricht IV / Florence Consensus Report // Gut.- 2012; 61: 646-664. DOI:10.1136/gutjnl-2012-302084.
22. Villoria A. Acid-related diseases: are higher doses of proton pump inhibitors more effective in the treatment of Helicobacter pylori infection? // Gastroenterol Hepatol.-2008; 31: 546-7.
23. Sheu B-S, Wu J-J, Lo C-Y, et al. Impact of supplement with Lactobacillus- and Bifidobacterium-containing yogurt on triple therapy for Helicobacter pylori eradication // Aliment. Pharmacol. Ther.- 2002; 16: 1669-1675. DOI: 10.1046/j.1365-2036.2002.01335.x.
24. Medeiros Jose A, and Pereira Marta-Isabel. The use of Probiotics in Helicobacter pylori Eradication Therapy // J. Clin. Gastroenterol.- 2013; 47 (1): 1-5. DOI: 10.1097/ MCG.0b013e3182702dbc.
25. Emara Mohamed Y, et al. Emerging Role of Probiotics in the Management of Helicobacter Pylori Infection: Histopathologic Perspectives // Helicobacter.- 2016; 21: 3-10. DOI: 10.1111/hel.12237.
26. Cosme Angel, et al. Antimicrobial Susceptibility-Guided Therapy Versus Empirical Concomitant Therapy for Eradication of Helicobacter pylori in a Region with High Rate of Clarithromycin Resistance // Helico-bacter.-2016; 21 (1): 29-34. DOI: 10.1111/ hel.12231.
27. Zhou Liya, et al. Tailored versus Triple plus Bismuth or Concomitant Therapy as Initial Helicobacter pylori Treatment: A Randomized Trial // Helicobacter.- 2016; 21 (2): 91-99. DOI: 10.1111/hel.12242.
28. Chen Han, et al. Tailored Therapy Versus Empiric Chosen Treatment for Helicobacter pylori Eradication // Medicine.-2016; 95 (7): 1-10. DOI: 10.1097/MD.0000000000002750.
29. McFarland LV, Huang Y, Wang L and Malfertheiner P. Systematic review and meta-analysis: Multi-strain probiotics as adjunct therapy for Helicobacter pylori eradication and prevention of adverse events //UEG journal.-2016; 4 (4): 546-561. DOI: 10.1177/2050640615617358.
30. Manfredi M, et al. Helicobacter pylori Infection in Clinical Practice: Probiotics and a Combination of Probiotics + Lactoferrin Improve Compliance, But Not Eradication, in Sequential Therapy // Helicobacter.- 2012; 17 (4): 254-263. DOI: 10.1111/j.1523-5378.2012.00944.x.
31. Tong JL, Ran ZH, Shen J, et al. Meta-analysis: the effect of supplementation with probiotics on eradication rates and adverse events during Helicobacter pylori eradication therapy // Aliment. Pharmacol. Ther. - 2007; 25: 155-68. DOI: 10.1111/j.1365-2036.2006.03179.x.
32. Sachdeva A, Nagpal J. Effect of fermented milk-based probiotic preparations on H. pylori eradication: a systematic review and meta-analysis of randomized-controlled trials //Eur. J. Gastroenterol. Hepatol.- 2009; 1: 45-53. DOI: 10.1097/MEG.0b013e-32830d0eff.
33. Szajewska H, Horvath A, Piwowarczyk A. Meta-analysis: the effects of Saccharomyces boulardii supplementation on Helicobacter pylori eradication rates and side effects during treatment // Aliment Pharmacol Ther.- 2010; 32: 1069-79. DOI: 10.1111/j.1365-2036.2010.04457.x.
34. Bumjo Oh, Bong-Soo Kim, Ji Won Kim, et al. The Effect of Probiotics on Gut Microbiota during the Helicobacter pylori Eradication: Randomized Controlled Trial // Helico-bacter.-2016;21 (3): 165-174. DOI: 10.1111/ hel.12270.
35. Min-Min Zhang, Wei Qian, Ying-Yi Qin, Jia He, Yu-Hao Zhou. Probiotics in Helicobacter pylori eradication therapy: A systematic review and meta-analysis // WJG.- 2015; 21 (14): 4345-4357. DOI: 10.3748/wjg.v21.i14.4345.
36. Старостин Б. Д., Старостина Г. А. Флоролакт при проведении антихеликобактерного режима // Гастроэнтерология Санкт-Петербурга. - 2013; 1: 15-18.
37. P Malfertheiner, F Megraud, CA O'Morain, JP Gisbert, EJ Kuipers, AT Axon, F Bazzoli, A Gasbarrini, J Atherton, DY Graham, R Hunt, P Moayyedi, T Rokkas, M Rugge, M Selgrad, S Suerbaum, K Sugano, EM El-Omar, on behalf of the European Helicobacter and Microbiota Study Group and Consensus panel // Gut.-2017; 66: 6-30. DOI:10.1136/ gutjnl-2016-312288.
38. O’Connor A, Fishback W, G'isbert J, O'Morain C. Treatment of Helicobacter pylori infection 2016 // Helicobacter.- 2016; 21 (Suppl. 1): 55-61. DOI: 10.1111/hel.12342.
39. De Witte C, Sczulz C, Smet A, Malthertheiner P. Other Helicobacter and gastric microbiota // Helicobacter.- 2016; 21 (Suppl. 1): 62-68. DOI: 10.1111/hel.12343.
Review
For citations:
Starostin B.D. New method of eradication therapy of Helicobacter pylori. Medical alphabet. 2017;1(9):23-29. (In Russ.)
Views:
372
Email this article 